Literature DB >> 33434240

Ultrasonography validation for early alteration of diaphragm echodensity and function in the mdx mouse model of Duchenne muscular dystrophy.

Antonietta Mele1, Paola Mantuano1, Adriano Fonzino1, Francesco Rana1, Roberta Francesca Capogrosso1, Francesca Sanarica1, Jean-Francois Rolland2, Ornella Cappellari1, Annamaria De Luca1.   

Abstract

The mdx mouse model of Duchenne muscular dystrophy is characterized by functional and structural alterations of the diaphragm since early stages of pathology, closely resembling patients' condition. In recent years, ultrasonography has been proposed as a useful longitudinal non-invasive technique to assess mdx diaphragm dysfunction and evaluate drug efficacy over time. To date, only a few preclinical studies have been conducted. Therefore, an independent validation of this method by different laboratories is needed to increase results reliability and reduce biases. Here, we performed diaphragm ultrasonography in 3- and 6-month-old mdx mice, the preferred age-window for pharmacology studies. The alteration of diaphragm function over time was measured as diaphragm ultrasound movement amplitude. At the same time points, a first-time assessment of diaphragm echodensity was performed, as an experimental index of progressive loss of contractile tissue. A parallel evaluation of other in vivo and ex vivo dystrophy-relevant readouts was carried out. Both 3- and 6-month-old mdx mice showed a significant decrease in diaphragm amplitude compared to wild type (wt) mice. This index was well-correlated either with in vivo running performance or ex vivo isometric tetanic force of isolated diaphragm. In addition, diaphragms from 6-month-old dystrophic mice were also highly susceptible to eccentric contraction ex vivo. Importantly, we disclosed an age-dependent increase in echodensity in mdx mice not observed in wt animals, which was independent from abdominal wall thickness. This was accompanied by a notable increase of pro-fibrotic TGF-β1 levels in the mdx diaphragm and of non-muscle tissue amount in diaphragm sections stained by hematoxylin & eosin. Our findings corroborate the usefulness of diaphragm ultrasonography in preclinical drug studies as a powerful tool to monitor mdx pathology progression since early stages.

Entities:  

Year:  2021        PMID: 33434240      PMCID: PMC7802948          DOI: 10.1371/journal.pone.0245397

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  47 in total

1.  Estimating the total ultrasound attenuation along the propagation path by using a reference phantom.

Authors:  Yassin Labyed; Timothy A Bigelow
Journal:  J Acoust Soc Am       Date:  2010-11       Impact factor: 1.840

2.  Skeletal muscle ultrasound: correlation between fibrous tissue and echo intensity.

Authors:  Sigrid Pillen; Ramon O Tak; Machiel J Zwarts; Martin M Y Lammens; Kiek N Verrijp; Ilse M P Arts; Jeroen A van der Laak; Peter M Hoogerbrugge; Baziel G M van Engelen; Aad Verrips
Journal:  Ultrasound Med Biol       Date:  2008-12-10       Impact factor: 2.998

3.  Ultrasound assessment of the diaphragm: Preliminary study of a canine model of X-linked myotubular myopathy.

Authors:  Aarti Sarwal; Michael S Cartwright; Francis O Walker; Erin Mitchell; Anna Buj-Bello; Alan H Beggs; Martin K Childers
Journal:  Muscle Nerve       Date:  2014-08-30       Impact factor: 3.217

4.  Magnetic Resonance Monitoring of Disease Progression in mdx Mice on Different Genetic Backgrounds.

Authors:  Ravneet Vohra; Abhinandan Batra; Sean C Forbes; Krista Vandenborne; Glenn A Walter
Journal:  Am J Pathol       Date:  2017-09       Impact factor: 4.307

5.  Quantitative muscle ultrasound detects disease progression in Duchenne muscular dystrophy.

Authors:  Craig M Zaidman; Jim S Wu; Kush Kapur; Amy Pasternak; Lavanya Madabusi; Sung Yim; Adam Pacheck; Heather Szelag; Tim Harrington; Basil T Darras; Seward B Rutkove
Journal:  Ann Neurol       Date:  2017-05-04       Impact factor: 10.422

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

7.  Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests.

Authors:  Rosa Burdi; Jean-François Rolland; Bodvael Fraysse; Karina Litvinova; Anna Cozzoli; Viviana Giannuzzi; Antonella Liantonio; Giulia Maria Camerino; Valeriana Sblendorio; Roberta Francesca Capogrosso; Beniamino Palmieri; Francesca Andreetta; Paolo Confalonieri; Leonarda De Benedictis; Monica Montagnani; Annamaria De Luca
Journal:  J Appl Physiol (1985)       Date:  2009-01-08

8.  Dll4 and PDGF-BB convert committed skeletal myoblasts to pericytes without erasing their myogenic memory.

Authors:  Ornella Cappellari; Sara Benedetti; Anna Innocenzi; Francesco Saverio Tedesco; Artal Moreno-Fortuny; Gonzalo Ugarte; Maria Grazia Lampugnani; Graziella Messina; Giulio Cossu
Journal:  Dev Cell       Date:  2013-03-07       Impact factor: 12.270

9.  Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.

Authors:  Roberta Francesca Capogrosso; Paola Mantuano; Kitipong Uaesoontrachoon; Anna Cozzoli; Arcangela Giustino; Todd Dow; Sadish Srinivassane; Marina Filipovic; Christina Bell; Jack Vandermeulen; Ada Maria Massari; Michela De Bellis; Elena Conte; Sabata Pierno; Giulia Maria Camerino; Antonella Liantonio; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  FASEB J       Date:  2018-01-03       Impact factor: 5.834

10.  Toward precision medicine in myotonic syndromes.

Authors:  Michela De Bellis; Diana Conte Camerino; Jean-François Desaphy
Journal:  Oncotarget       Date:  2017-02-28
View more
  1 in total

1.  β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation.

Authors:  Paola Mantuano; Brigida Boccanegra; Elena Conte; Michela De Bellis; Santa Cirmi; Francesca Sanarica; Ornella Cappellari; Ilaria Arduino; Annalisa Cutrignelli; Angela Assunta Lopedota; Antonietta Mele; Nunzio Denora; Annamaria De Luca
Journal:  Biomolecules       Date:  2021-11-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.